Company intelligence / Profile preview

MavriX Bio

Ownership: Private
Development stage: Commercial

Overview

MavriX Bio is advancing MVX-220, an investigational adeno-associated virus (AAV) gene replacement therapy for Angelman syndrome. The FDA has cleared its IND application, enabling the first clinical trial in humans. This represents a significant milestone as there are currently no approved disease-modifying treatments for Angelman syndrome. Clinical trial details and timelines will be announced soon.

Therapeutic areas: Neurology
Modalities: Gene therapyAdeno-associated virus (AAV) gene therapyBiologic (as AAV vectors are biologics)
Industry: Biotech

Drug pipeline

1 asset

MVX-220

Unknown

Partnerships

FAST / AS²Bio acceleratorresearch foundation support from Dr. Jim Wilson’s laboratory at University of Pennsylvania/Gemma Bio

Beyond the preview

Go deeper on MavriX Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MavriX Bio.